J&J joins $10.6M round for developer of stem cell treatment

07/11/2013 | Xconomy

Stem cell startup ViaCyte secured $10.6 million in a private equity funding round in which Johnson & Johnson, the Johnson Trust and Sanderling Ventures participated. The funding matches the $10.1 million grant approved last year by the California Institute for Regenerative Medicine to support clinical trials of ViaCyte's encapsulated cell therapy product, VC-01, for treatment of type 1 and insulin-dependent type 2 diabetes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC